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Peripheral inﬂammation triggers exacerbation in the central brain’s ongoing damage in several neurodegenerative diseases.
Systemic inﬂammatory stimulus induce a general response known as sickness behaviour, indicating that a peripheral stimulus
can induce the synthesis of cytokines in the brain. In Parkinson’s disease (PD), inﬂammation was mainly associated with microglia
activationthatcanunderlietheneurodegenerationofneuronsinthesubstantianigra(SN).Peripheralinﬂammationcantransform
the “primed” microglia into an “active” state, which can trigger stronger responses dealing with neurodegenerative processes.
Numerous evidences show that systemic inﬂammatory processes exacerbate ongoing neurodegeneration in PD patient and animal
models. Anti-inﬂammatory treatment in PD patients exerts a neuroprotective eﬀect. In the present paper, we analyse the eﬀect of
peripheral infections in the etiology and progression in PD patients and animal models, suggesting that these peripheral immune
challenges can exacerbate the symptoms in the disease.
1. Neurodegenerative Diseases and
Systemic Inﬂammation
Inﬂammation is a defensive reaction against harmful stimuli
that can induce a defensive response in the body. In the
central nervous system (CNS), the main innate immune
defensive role is played by the immunocompetent resident
cells, the microglia [1]. Neurodegenerative diseases present
microglia activation as the main hallmark, which can
changeitsmorphologyfromquiescentandramiﬁed(resting)
towards a round ameboidal shape (activated) [2]. Resting
microglia displays a low-level expression of membrane
receptors, such as CD45, CD14, and CD11b [1]. Activated
microglia exhibits upregulation of cell surface receptors and
proinﬂammatory and anti-inﬂammatory cytokines, such as
major histocompatibility complex (MHC) class II, CD40,
CD80, CD86, CD11b (reviewed by [3]) demonstrating
changes in their activity [4, 5]( Figure 1). Microglia can
be activated by proinﬂammatory stimuli, but microglia
activation does not always exert a proinﬂammatory reaction.
Microglialactivationinsomeneurodegenerativediseaseswas
not accompanied by proinﬂammatory cytokine secretions
[6, 7]. Depino et al., 2003 demonstrated that microglial cells
induced an increase in IL-1β mRNA in the substantia nigra
(SN) but no translation of this cytokine was observed in
an animal model of PD. These observations prompted the
idea of “primed microglia” to describe the atypical microglia
state, which precedes a further neurotoxic microglial acti-
vation as a consequence of a secondary proinﬂammatory
stimulus [8, 9]. Microglia activation increases neurotoxicity
and, therefore, contributes to neurodegeneration through
the release of free radicals such as superoxide radicals,
nitric Oxide (NO), inducible nitric oxide synthase (iNOS)
[10–13], and proinﬂammatory, immunomodulatory and
anti-inﬂammatory cytokines, such as IL-1β,T N F - α,I L -
6, IL-8, IL-12, IL-15, and IL-10 [4, 14, 15]. Central or
peripheral inﬂammation can transform the “primed” state
of microglia into an “active” state, which can trigger or
induce stronger responses dealing with neurodegenerative
processes. Therefore, inﬂammation was mainly associated
with microglia activation that can underlie the neurodegen-
eration of dopaminergic neurons of the SN.
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Figure 1: Schematic diagram showing the relationship between peripheral inﬂammation and neuronal loss in PD. Neurodegenerative
diseases present microglial activation as the main hallmark, which can change its morphology from resting (ramiﬁed) towards an activated
round shape (ameboidal). The intermediate stage, “primed microglia”, describes the atypical microglial stage, which precedes a further
neurotoxic microglial activation as a consequence of a secondary pro-inﬂammatory stimulus. This stimulus can come from the periphery,
either through neural or humoral pathways. Activated microglia release pro-inﬂammatory cytokines which can act on neuronal integrity.
prevents entry of pathogens and immune cells into the
parenchyma. However, this statement has changed in the
last few years, because the communication between central
CNS and periphery is more ﬂuid than previously considered.
In many neurological disorders, the immune system plays
an important role in the progression of these diseases.
Indeed, BBB breakdown and inﬂammation appear to play a
major role in the pathology of numerous neurodegenerative
diseases compromising the vascular unit and inducing
leukocyte migration within the brain parenchyma (reviewed
in [16]).
Systemic inﬂammatory stimuli circulate into the blood
andcangetinto the braininducing the synthesis of cytokines
that, in turn, can induce a general inﬂammatory response
including liver acute phase response and the components
to induce sickness behaviour [17–21]. Proinﬂammatory
stimulus would trigger the secretion of proinﬂammatory
molecules in the diseased brain [6]( Figure 1).
Peripheral inﬂammation sparks oﬀ exacerbation in the
central brain’s ongoing damage in several neurodegenerative
diseases,suchasAlzheimer’sdisease(AD),multiple sclerosis,
Parkinson’s disease, prion disease, stroke, and Wallerian
degeneration [8, 9, 22–26]. Indeed, Perry’s group has
studied the eﬀect of peripheral inﬂammation on behavioural
response, demonstrating a worsening of degenerative pro-
cesses related to delirium in AD [19, 27]. In particular,
PD patients and animal models with ongoing inﬂammatory
neurodegeneration processes evidence exacerbation of the
neurodegenerative process after a peripheral inﬂamma-
tory stimulus [28–33]. Aging was also proposed to prime
microglia cells [14]. MHC-II was increased in aged brains
and i.p administration of LPS resulted in an increased
inﬂammatory response in elderly patients [15, 34–36].
Previously, we described that the communication
between the brain and the periphery as a one way road.
However, the central-peripheral relationship is more com-
plex, and the traﬃcb e c o m e sat w ow a yr o a d .A c u t eb r a i n
injuryinducesearlyhepaticexpressionofchemokines,which
in turn produce movement of leukocytes into the blood and
subsequently brain and liver inﬂammation [9, 37–40]. The
production of cytokines by the liver as a systemic response to
CNS injury is a component of CNS response. The injection
of IL-1 into the brain is associated with hepatic expression of
CXCL1, which is responsible for neutrophil recruitment toParkinson’s Disease 3
the brain [40]. Hepatic TNF-α is also a component of the
systemic response to IL-1β injured brain [39]. TNF-α was
alsofoundassociatedwithIL-1β inducedsickness behaviour,
in addition, the inhibition of peripheral TNF-α can block
somecomponentsofsicknessbehaviourinducedbycentrally
injected IL-1β [41]. Peripheral TNF-α appears to be involved
in microglial activation and the subsequent recruitment of
monocytes into the brain in a model of peripheral liver
inﬂammation resulting from bile duct ligation [42]. There-
fore, the hepatic production of cytokines and chemokines
may also be considered as a target to neutralize acute and
chronic brain injury (Figure 1).
In summary, systemic inﬂammatory events could inﬂu-
ence the aetiology and progression of many ongoing degen-
erativediseases.Despitepreviousevidences,thecontribution
of peripheral inﬂammation to the progression of neurode-
generative diseases is not fully understood. Analysis of the
inﬂammatory components of the systemic response that
inﬂuence ongoing damage in the brain should be carefully
studied and considered as potential therapeutic targets.
2. Routes of Systemic Inﬂammation
The circulating cytokines and other inﬂammatory molecules
that are produced by systemically induced insults can aﬀect
the brain through several routes, mainly humoral or neural
pathways. The humoral route between the nervous and the
immune systems has been related to sickness behaviour,
characterized by fever, anorexia, and alteration in the
behaviour. The humoral mechanisms are mostly related to
the presence of the blood brain barrier (BBB). The BBB
regulates the passage of substances from the blood to the
brain (reviewed in [43]). This barrier can be seriously
aﬀected in brain injury. There are several ways of crossing
the barrier: (1) the substances can enter through the areas
in the CNS that lack BBB, like the circumventricular organs,
(2) some molecules may cross the BBB using speciﬁc
transporters (e.g., cytokines, amines), (3) BBB permeability
may be increased as a consequence of the stimuli per se, (4)
endothelial cells can be activated by the peripheral stimuli,
inducing the synthesis of molecules within the CNS [44–
46], and (5) the choroidplexus transiently alters its gene
expression proﬁle as a response to peripheral LPS stimuli
[47]. Systemic injection of LPS can cause BBB damage and
allow the entrance of granulocytes from the periphery to
the brain [48]. Indeed, BBB breakdown was described in PD
patients and animal models [49–53]. The disruption of the
BBB allows the extravasation of proinﬂammatory cytokines
andimmunecellswhichcanactivatemicrogliaintheSNand,
therefore, induce neurodegeneration.
The second route of neuroimmune communication,
known as the neural pathway, is related to the transmission
of peripheral inﬂammatory signals through the autonomic
nervous system. The most important aﬀerent responsible
for the neural transmission of peripheral signals is the
vagus nerve. Neural pathways are stimulated by peripheral
signals that rapidly increase the levels of brain cytokines
[2, 54, 55]. Subdiaphragmatic lesion of the vagus nerve
and vagotomy attenuate brain cytokine production and
behavioural eﬀects after a systemic challenge [56–60]. IL-
1β receptors are present on vagal ganglia close to liver
and lymphatic nodes [61]. Inﬂammatory processes in the
periphery are conducted to the brain via the vagal aﬀerents
and, as a response, the vagal eﬀerents act on the systemic
inﬂammatory events through acetylcholinesterase secretions
[25, 54, 62]. In addition, Kamer et al., 2008, suggested that
the neural pathway is also involved in the transmission of
inﬂammatory signals from the oral cavity in periodontal
diseases, and this mechanism would be related to worsening
of AD symptoms [62].
A third potential pathway was recently proposed using
a model of inﬂammatory liver injury [42]. These authors
suggested the existence of cellular messengers, activated
monocytes, which were recruited into the brain. These
activated monocytes secreted messenger molecules, such as
TNF-α and MCP-1 (which has been classically deﬁned as
humoral) within the brain during systemic inﬂammatory
diseases [42, 63].
3.Parkinson’sDisease andSystemic
Inﬂammation: Evidencefrom the Clinic
Peripheral immunological challenges and chronic inﬂam-
matory diseases inﬂuence the pathogenesis and progression
of PD. The communication between the immune and the
nervous system is very ﬂuid, cytokines being the main
mediators of inﬂammation in both brain and periphery.
There is evidence that suggests a link between peripheral
inﬂammation and PD. The inﬂuenza pandemic during
the second world war was associated with an increase in
PD in the population [64]. In addition, people infected
with Japanese encephalitis virus and H5N1 inﬂuenza virus
presented a higher risk for developing PD [65, 66].
Activated microglial cells and proinﬂammatory cytok-
ines, including IL-1β,T N F - α, and IL-6, have been described
in SN of postmortem tissue [67, 68], as reviewed in [69].
In vivo studies have also demonstrated that the serum and
cerebrospinalﬂuidofPDpatientshavehigherlevelsofIL-1β,
TNF-α, and IL-2 and also CD4+ and CD8+ Tl y m p h o c y t e s ,
indicating peripheral activation of lymphocytes [70–74].
The relationship between inﬂammation and PD has been
demonstrated by several authors [3, 69, 75–79]. Subject
carriers of IL-1β-511 homozygous variant genotype show a
2-fold increased risk of PD, which induced an increment of
susceptibility of dopaminergic neurons to toxicity [80]. On
the other hand, increased peripheral cytokine production
inﬂuences PD progression. PD patients showed elevated
serum levels of TNF-α and TNF-α receptor 1 compared to
control subjects, which can contribute to PD pathogenesis
[72, 81, 82]. Also, elevated plasma concentration of IL-6
correlates with increased risk of PD [52].
Although late onset sporadic PD was recently associated
with genetic variation in the HLA DR region, stressing
the importance of the immune component in this disease,
[83] PD can also be triggered by diseases that induce sys-
temic infections. Indeed, PD patients often suﬀer infectious
diseases, and the main causes of death are pneumonia
and respiratory infections [30–33]. It was described that4 Parkinson’s Disease
gastrointestinal infections could contribute to a worsening
of PD [84, 85]. However, peripheral immune response
in PD patients has shown contradictory results, because
some authors have found unaﬀected levels of cytokines
and immune parameters in PD patients [73, 86]. Several
studies support a role for the adaptative immune system
in PD etiology and progression. The presence of cytotoxic
Tl y m p h o c y t e( C D 4 + and CD8+) has been described to
inﬁltrate the SN of patients and animal PD models [87–
89]. The inﬂux of these peripheral cells into the brain
parenchymacouldindicateaBBBdysfunctioninPDpatients
[49, 69]. Indeed, the adaptative immune system might
modulate microglia activation in PD pathogenesis [90].
Anti-inﬂammatory therapies were used in PD patients to
decrease the eﬀect of inﬂammatory reactions. The NSAIDs
had an anti-inﬂammatory and neuroprotective eﬀect in
PD. Chronic users of nonsteroidal anti-inﬂammatory drugs
(NSAIDs), such as ibuprofen, a COX-1 and COX-2 inhibitor,
exhibited diminished PD incidence [91, 92]. Minocycline, a
derivate of tetracycline that crosses the BBB, also improves
neuronal survival in PD. This molecule was described as
an inhibitor of microglial activation, proliferation, and
release of proinﬂammatory cytokines [93–95]. It should
be taken into consideration that inﬂammation has a dual
action in neurodegeneration, also inducing molecules useful
in promoting repair and regeneration of damaged tissue.
Therefore, considering the beneﬁcial eﬀects of some of the
inﬂammatory components, restriction of the inﬂammatory
response is not always the best choice. Better alternative ther-
apies should be considered in order to really make progress
in this ﬁeld (reviewed in [96]). These authors propose a
multidisciplinary research aimed at protein clearance and
immunoprotection induced by T cell regulators.
The studies related to the inﬂammatory processes in PD
should be carefully evaluated in order to develop more suit-
able tools that will allow us to diminish neurodegeneration
and improve the quality of life in PD patients.
4.Parkinson’sDisease andSystemic
Inﬂammation: ExperimentalEvidences
The link between peripheral infection and PD neurodegen-
erationinbothpatientandanimalmodelswasdemonstrated
in several studies. LPS causes a systemic inﬂammatory
reaction known as sickness behaviour characterized by fever,
anorexia, weight loss, and reduction of activity [97]. A
similar response can be obtained with i.p injection of proin-
ﬂammatory cytokines, such as IL-1β and IL-6 (reviewed in
[58]). The resident microglia in the brain responds to these
stimuli and generates sickness behaviour. Taking this into
consideration, ongoing inﬂammatory degenerative processes
can be accelerated by systemic inﬂammation. Peripheral
inﬂammatory states, such as infection and injury, can
exacerbate neuronal death stimulating “primed microglial
cells” towards a more aggressive state.
PD animal models support the previous hypothesis.
Pregnant rats exposed to intraperitoneal (i.p.) injection
o fL P Sr e s u l t e di nad e c r e a s e dn u m b e ro fd o p a m i n e r -
gic neurons in the pups when compared to nonexposed
controls [98]. In concordance with Carvey’s results, rat
foetuses exposed to LPS are more susceptible to 6-OHDA
in adulthood [99, 100]. In adult animals, there is also
data that strongly suggests the role of peripheral inﬂam-
mation in the ongoing PD model. Animals with central
dopaminergic hypoactivity are associated with an increased
peripheral inﬂammatory response after bacterial LPS injec-
tion [101]. Gastrointestinal dysfunctions are related to
peripheral inﬂammation; indeed, ulcerative colitis correlates
with increased levels of TNF-α,I L - 1 β,I L - 6 ,a n da c u t e
phase proteins in rat serum [102]. Peripheral inﬂammation
induced by ulcerative colitis worsened the eﬀects induced
by intranigral LPS, such as loss of dopaminergic neurons,
microglial activation, and alteration in BBB permeability
[102]. All previous data indicate that the relationship
between the peripheral immune system and the central
dopaminergic system is very close.
Proinﬂammatory cytokines, including IL-1β and TNF,
have been described as involved in promoting neurodegener-
ation. These cytokines induced the synthesis of chemokines,
producing in turn the recruitment of neutrophils and
monocytes from the blood stream. IL-1β alone might induce
the cellular recruitment to the brain parenchyma [103–106].
The eﬀects of IL-1β in the progression of neurodegenerative
diseasehavebeenstudiedbyseveralgroups[9,23,28,29,37–
39, 104, 105, 107]. Systemic challenge with LPS induces
CNS IL-1β synthesis and sickness behaviour in animals
with ongoing central inﬂammation [19]. However, systemic
inﬂammation actively inhibits recruitment of leukocytes
in the CNS, when LPS is injected 2 hours before the
intracerebroventricular injection of IL-1β [108]. Systemic
inﬂammation generated by IL-1β induces BBB disruption
and increased brain damage in a model of stroke [9, 23].
In addition, chronic systemic expression of IL-1β was able
to exacerbate neuronal demise and microglial activation in
the SN of both 6OHDA and an inﬂammatory PD model
[28, 29], increasing the clinical impact of these ﬁndings [29].
Exacerbation of neurodegeneration in 6OHDA model was
accompanied by an increase in activated microglia in the
animals that received IL-1β as peripheral stimulus [28]. The
same group has demonstrated that a peripheral systemic
stimulus causes exacerbation of the behavioral symptoms
and neuronal loss in an inﬂammatory PD model based on
the chronic IL-1β expression in the striatum. These events
were accompanied by massive activation of microglia with
the concomitant expression of MHC-II [29]. Therefore,
the increment in the neurodegenerative process can be
correlated with an increase in MHC-II expression induced
by a peripheral stimulus [29].
Peripheral induction of TNF-α activates brain microglia
that, in turn, produces proinﬂammatory factors and, as a
consequence, induces dopaminergic neuronal loss in the SN
[109]. Indeed, dominant negative TNF-α inhibitor displayed
neuroprotective properties in both 6OHDA and chronic LPS
rat model [110].
However, on the contrary, some inﬂammatory compo-
nents of the adaptative immune response were described
as immunomodulators of the neurodegenerative pro-
cess. CD4+ CD25+ regulatory T cells (Tregs) suppressParkinson’s Disease 5
neuroinﬂammation, attenuate microglia response, and
induce nigrostriatal protection in a MPTP model [111,
112]. These cells exert their activity by upregulation of
brain-derived neurotrophic factor (BDNF), glial-derived
neurotrophic factor (GDNF), IL-10 and transforming
growth factor (TGF-β), and downregulating proinﬂamma-
tory cytokines and ROS production (reviewed in [111, 113]).
These data suggest that Tregs exert their action modulating
the immune response, possibly via the interaction between
the peripheral and the CNS immune system (Reviewed in
[89, 96]). Immunotherapy should be directed towards a Th2
Treg response in order to downregulate the Th1 response
[112]. The interaction of Tregs with cells or molecules may
modulate the adaptative immune response. Therefore, alter-
ations of the immune system as a consequence of peripheral
inﬂammation could change the immunological properties of
Tregs, inducing a phenotype not suitable for the beneﬁcial
Treg activation. Further studies should be undertaken before
Tregs immunization treatment is to be considered for PD
patients with ongoing peripheral infections.
The use of anti-inﬂammatory drugs has been extensively
studied in PD animal models (reviewed in [78]). The role
of COX has been studied in an MPTP model demonstrating
that indomethacin protects dopaminergic neurons in SN
[114]. Treatment with rofecoxib and celecoxib also induces
ap r o t e c t i v ee ﬀect in the SN neurons [115–117]. In addition,
the use of dexamethasone was demonstrated to reduce the
neuronal loss in a 6-OHDA plus LPS exacerbation and, in
an inﬂammatory model of PD, exacerbated with IL-1β as a
peripheral inﬂammatory stimulus [28, 29].
The interaction between brain inﬂammation and sys-
temic inﬂammation may be responsible for the progression
of neurodegenerative disease. Studying the relationship
between CNS and periphery could help ﬁnd targets for
therapeutic treatments.
5. Conclusion
Central or systemic inﬂammatory insults should be con-
sidered as risk factors in the PD aetiology and pro-
gression. The clear knowledge of mechanisms implicated
in immune/nervous communication and the mechanisms
involved in microglia activation and their switch to an
aggressive phenotype could help improve the therapeutic
tools leading to better patient quality of life, reducing the
exacerbation of PD symptoms, and delaying the progression
of the disease.
In addition, acute brain injury induces early hepatic
expression of chemokines, which in turn produce recruit-
ment of leukocytes into the blood and subsequently brain
and liver inﬂammation via a chemokines and cytokines
web.
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